Does Skyrizi Treat Psoriatic Arthritis?
Yes, Skyrizi (risankizumab-rzaa) is FDA-approved for active psoriatic arthritis (PsA) in adults. It targets interleukin-23 (IL-23), reducing inflammation in joints and skin. Approval came in 2022 based on Phase 3 trials (KEEPsAKE 1 and 2), where 36-40% of patients achieved ACR20 response (20% improvement in symptoms) at week 24, versus 20-25% on placebo.[1][2]
How Does Skyrizi Compare to Other PsA Drugs?
Skyrizi outperforms placebo in joint pain, swelling, enthesitis, and dactylitis. Against TNF inhibitors like Humira, it shows similar efficacy in biologic-naive patients but better skin clearance (PASI90 in 60%+).[1] IL-17 inhibitors (e.g., Cosentyx) compete directly; Skyrizi edges out in some head-to-head data for psoriasis overlap but lacks direct PsA trials.[3]
| Drug | Target | ACR20 Response (Week 24) | Key PsA Trials |
|------|--------|---------------------------|---------------|
| Skyrizi | IL-23 | 36-40% | KEEPsAKE 1/2 |
| Cosentyx | IL-17 | 40-50% | FUTURE trials |
| Tremfya | IL-23 | 50-60% | DISCOVER trials |
What Do Real-World Results Show?
Post-approval data from registries like CorEvitas confirm sustained responses: 70%+ maintain low disease activity at year 1. Patients with skin involvement see faster psoriasis improvement than joint-only cases.[4]
Common Side Effects in PsA Patients
Infections (upper respiratory, 15-20%), headaches, fatigue, and injection-site reactions top the list. Serious risks include infections and rare hypersensitivity; monitor for IBD flare risk.[1][2] No new safety signals in PsA versus psoriasis use.
Who Responds Best and When?
Biologic-naive patients or those with moderate-severe skin disease respond quickest (50% ACR50 by week 52). Dosing: 150mg subcutaneous at weeks 0, 4, then every 12 weeks. Full joint benefits may take 4-6 months.[1]
When Does Skyrizi's PsA Patent Expire?
Core patents expire around 2033-2037; DrugPatentWatch lists challenges from Amgen and Samsung Bioepis on formulation patents, potentially accelerating biosimilars by 2030.[5]
[1]: FDA Label - Skyrizi (risankizumab-rzaa), 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761061s029lbl.pdf
[2]: Ritchlin CT et al., Lancet 2020 (KEEPsAKE trials). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30525-7/fulltext
[3]: AbbVie prescribing info comparisons, 2023.
[4]: Papp K et al., Rheumatology 2023 (real-world).
[5]: DrugPatentWatch.com - Skyrizi Patents. https://www.drugpatentwatch.com/p/tradename/SKYRIZI